Altamira Therapeutics Ltd.

Good morning and welcome to the Altamira's Therapeutics Business Update and Full Year 2023 Earnings Conference Call. On today's call are Thomas Meir, Altamira's Founder, Chairman and the Chief Executive Officer, and Kovadonga Panida, Altamira's Chief Operating Officer. Earlier today, Altamira issued a news release with the full year 2023 financial results as well as a comprehensive business update. The release is available on the company's website at www.altamiratherapeutics.com and has been filed with the SEC. During today's call, the company will be making forward-looking statements within the meaning of the Private Securities Litigation Act of 1995. These include statements that address future operating, financial or business performance or its strategies or expectations. Forward-looking statements are based on management's current expectations and beliefs and involve significant risk and uncertainties that could cause actual results, development and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include, but are not limited to, the timing and conduct of our clinical trials, the clinical utility of our product candidates, the timing or likelihood of regulatory filings and approvals, our intellectual property proposition and our financial position, as well as those described in the risk factors section in our annual report on Form 20F. and future filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent the company's views only as of today and should not be replied upon as representing its views as of any subsequent date. While it may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so even if its views change. With that, I will now hand the call over to Altamira Therapeutics CEO, Thomas Meyer.

Please go ahead.

Thank you, Razia. Hello, everyone, and thank you for joining our business update and full year 2023 earnings call. I will kick off the call by providing an overview of recent corporate developments, as well as an update on our strategy. Our COO, Covadonga Panera, will then discuss the progress in our new core business of RNA delivery. Finally, I will discuss our financials and outlook for 2024 before opening the call for any questions. Reflecting on where Altamira stood one year ago and where we are today, I'm pleased to say that we made great progress. and emerged as a stronger and more focused company. We keep progressing with the RNA delivery business. More and more potential applications for our oligophore and semaphore nanoparticle technology are being identified, and we just recently concluded our second collaboration agreement with another exciting biotech company. Extrahepatic delivery of RNA and efficient intracellular release or hot topics in the industry. With the recent partial spinoff of our venture legacy business, we took a significant first step on our journey towards becoming a fully focused RNA delivery company. And we expect to complete the strategic repositioning of the company through partnering of our AM125 legacy asset in 2024. Those legacy assets have substantial intrinsic value, and we just started to unlock that potential. We managed to streamline our cost structure and reduce cash burn very significantly. At the same time, we cleaned up our balance sheet by paying off all financial debt earlier than planned and rebuilt shareholders' equity from a deficit to 6.5 million Swiss francs or more than 7.1 million US dollars. This puts us financially in a much stronger position. We are seeing great potential in the RNA space and are now much better positioned than one year ago to take advantage of these exciting opportunities. With this, I'm handing the call over to Covadonga Panera, our Chief Operating Officer who will provide you with an update on our RNA delivery business.